Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
2.100
-0.040 (-1.87%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Kyverna Therapeutics Employees
Kyverna Therapeutics had 112 employees as of December 31, 2024. The number of employees increased by 16 or 16.67% compared to the previous year.
Employees
112
Change (1Y)
16
Growth (1Y)
16.67%
Revenue / Employee
n/a
Profits / Employee
-$1,138,188
Market Cap
90.76M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 112 | 16 | 16.67% |
Dec 31, 2023 | 96 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
KYTX News
- 4 weeks ago - Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results - PRNewsWire
- 5 weeks ago - Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025 - Seeking Alpha
- 7 weeks ago - Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference - PRNewsWire
- 2 months ago - KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit - PRNewsWire
- 2 months ago - Investors in Kyverna Therapeutics, Inc. Should Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights – KYTX - GlobeNewsWire
- 2 months ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics - Accesswire
- 2 months ago - Final Deadline for the Kyverna Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - KYTX - PRNewsWire
- 3 months ago - KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit - PRNewsWire